2018(36)Ba(9)Stocks(1515)Healthcare(52)Look(51)
Introduction
2018 was a transformative year for the US healthcare industry, with numerous stocks experiencing significant growth and fluctuations. In this article, we delve into the top-performing healthcare stocks of 2018, highlighting the key factors that contributed to their success and analyzing their current standing.
Top US Healthcare Stocks in 2018
1. Amgen Inc. (AMGN)
Amgen Inc., a biotechnology company, topped the list of healthcare stocks in 2018. The company's revenue increased by 13% to $23.5 billion, driven by strong sales of its anemia and cancer drugs. Amgen's success can be attributed to its innovative pipeline, which includes treatments for osteoporosis, cardiovascular diseases, and neurodegenerative disorders.
2. Johnson & Johnson (JNJ)
Johnson & Johnson, a leader in pharmaceuticals, medical devices, and consumer healthcare products, also performed well in 2018. The company's revenue reached $81.5 billion, marking a 7.7% increase from the previous year. Johnson & Johnson's robust product portfolio and global presence played a crucial role in its growth.
3. Gilead Sciences Inc. (GILD)
Gilead Sciences Inc., a biopharmaceutical company, witnessed a remarkable turnaround in 2018. After facing setbacks in the previous years, Gilead's revenue increased by 15% to $24.4 billion. The company's success can be attributed to its new drugs, including Veklury, which treats the flu, and Zydelig, which treats blood cancer.
4. AbbVie Inc. (ABBV)
AbbVie Inc., a global biopharmaceutical company, ranked fourth on our list. The company's revenue grew by 14.7% to $33.7 billion. AbbVie's success is largely due to its blockbuster drug, Humira, which is used to treat rheumatoid arthritis, ulcerative colitis, and Crohn's disease.
5. Merck & Co. Inc. (MRK)
Merck & Co. Inc., a global pharmaceutical company, also made a strong showing in 2018. The company's revenue reached $44.3 billion, marking a 10.2% increase. Merck's success can be attributed to its pipeline of new drugs, including Keytruda, which treats cancer, and Lysteda, which treats heavy menstrual bleeding.
Key Factors Contributing to Success
Several factors contributed to the success of these healthcare stocks in 2018:
- Innovative Pipeline: Companies with robust pipelines of new drugs experienced significant growth, as investors looked for promising treatments for various diseases.
- Global Expansion: Companies that expanded their presence in emerging markets saw increased revenue, as demand for healthcare products and services grew.
- Acquisitions: Many companies invested in acquisitions to expand their product portfolios and gain access to new markets.
Conclusion
2018 was a remarkable year for the US healthcare industry, with several stocks performing exceptionally well. Companies with innovative pipelines, global expansion, and strategic acquisitions were able to capitalize on the opportunities available in the market. As we move forward, these trends are likely to continue, making healthcare stocks a compelling investment opportunity for investors.
Dow Jones